Ronald M Fleming

US Patent:

20140128434, May 8, 2014

Filed:

Jun 28, 2012

Appl. No.:

14/128007

Inventors:

Kurt R. Auger - Collegeville PA, US
Mohammed M. Dar - Research Triangle Park NC, US
Ronald A. Fleming - Research Triangle Park NC, US

International Classification:

A61K 31/4439

US Classification:

514341

Abstract:

This invention relates to a method of treating cancer in a human in need thereof by determining the presence or absence of a detectable amount of a gene product of the Neurofibromin-2 (NF2) gene in a sample from the human, and administering to the human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected. This invention also relates to a method of treating cancer in a human in need thereof, comprising determining the presence or absence of a detectable amount of a functional isoform 1 protein of the NF2 gene, or a functional fragment thereof, in a sample from the human, and administering to the human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected.